GUARD THERAPEUTICS INTERNATIONAL AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.80 SEK | +1.41% |
|
-1.37% | -19.55% |
| 08-29 | First Patient Dosed in Guard Therapeutics' Phase 2B Study POINTER | CI |
| 08-27 | Guard Therapeutics Plans New SEK80 Million Rights Issue to Fund Kidney Drug Study | MT |
Company Valuation: Guard Therapeutics International AB
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 161.8 | 200.4 | 452.2 | 273.1 | 360.2 | 347.2 | - | - |
| Change | - | 23.81% | 125.68% | -39.61% | 31.9% | -3.61% | - | - |
| Enterprise Value (EV) 1 | 107.9 | 110.3 | 452.2 | 72.77 | 276.5 | 239.2 | 330.2 | 347.2 |
| Change | - | 2.28% | 309.88% | -83.91% | 279.94% | -13.47% | 38.04% | 5.15% |
| P/E ratio | -3.62x | -6.84x | -3.56x | -2.49x | -3.18x | -4.92x | -4.65x | 1.75x |
| PBR | - | - | 2.57x | 1.58x | 5.4x | 4.02x | 29.4x | 1.65x |
| PEG | - | 0.2x | -0x | 0.2x | 0.1x | 0.1x | -0.8x | -0x |
| Capitalization / Revenue | - | - | - | - | - | - | - | 1.16x |
| EV / Revenue | - | - | - | - | - | - | - | 1.16x |
| EV / EBITDA | -2.7x | -2.75x | -5.52x | -0.63x | -2.4x | -2.63x | -3.63x | 1.43x |
| EV / EBIT | -2.44x | -2.74x | -5.52x | -0.63x | -2.4x | -2.63x | -3.63x | 1.43x |
| EV / FCF | -1.79x | -2.91x | -5.83x | -0.71x | -2.38x | -2.37x | -3.63x | - |
| FCF Yield | -55.9% | -34.4% | -17.2% | -140% | -42% | -42.2% | -27.6% | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -14.5 | -9.5 | -18.5 | -16 | -11.26 | -5.85 | -6.19 | 16.5 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - | 299 |
| EBITDA 1 | -39.9 | -40.12 | -81.9 | -114.9 | -115.1 | -91 | -91 | 243 |
| EBIT 1 | -44.28 | -40.28 | -81.9 | -114.9 | -115.1 | -91 | -91 | 243 |
| Net income 1 | -45.16 | -40.28 | -82.03 | -112.8 | -113.3 | -86 | -91 | - |
| Net Debt 1 | -53.97 | -90.04 | - | -200.3 | -83.74 | -108 | -17 | - |
| Reference price 2 | 52.50 | 65.00 | 65.90 | 39.80 | 35.80 | 28.80 | 28.80 | 28.80 |
| Nbr of stocks (in thousands) | 3,082 | 3,082 | 6,862 | 6,862 | 10,062 | 12,056 | - | - |
| Announcement Date | 27/02/20 | 24/02/21 | 22/02/22 | 22/02/23 | 21/02/24 | - | - | - |
1SEK in Million2SEK
Estimates
P/E ratio, Detailed evolution
| P/E ratio | EV / Sales | EV / EBITDA | Yield (Y) | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -4.92x | - | -2.63x | - | 33.82M | ||
| 46.75x | 6.21x | 21.87x | +0.86% | 46.02B | ||
| 31.55x | 3.62x | 15.07x | -.--% | 44.31B | ||
| -101.86x | 13.66x | -233.58x | -.--% | 31.68B | ||
| 74.43x | 11.32x | 40.44x | +0.26% | 29.63B | ||
| -7.94x | 6.51x | -6.14x | -.--% | 28.02B | ||
| 32.72x | 3.22x | 14.89x | -.--% | 25.05B | ||
| 13.96x | 4.61x | 8.99x | -.--% | 15.38B | ||
| 59.5x | 9.24x | 26.35x | +0.45% | 11.34B | ||
| 28.97x | 4.52x | 21.68x | -.--% | 10.39B | ||
| Average | 17.32x | 6.99x | -9.31x | +0.17% | 24.19B | |
| Weighted average by Cap. | 17.84x | 7.03x | -15.15x | +0.22% |
Year-on-year evolution of the PER
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- GUARD Stock
- Valuation Guard Therapeutics International AB
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition